Piscataway, NJ, February 1, 2019 – Legend Biotech USA, Inc (“Legend”) announced today that the company has recently joined the American Society for Blood and Marrow Transplantation (ASBMT™) Corporate Council. Representatives from Legend plan to actively participate in ASBMT Corporate Council forums.

Participation in the ASBMT Corporate Council provides Legend Biotech with the opportunity to share knowledge, pool resources and engage in problem-solving dialogues with companies and thought leaders in the industry with specific focus on cellular therapies.

The ASBMT Corporate Council forums are held twice each year and encourage a collaborative discussion about emerging trends, best practices, policies and challenges.

“We are excited and honored to participate in the ASBMT Corporate Council,” said Yuan Xu, CEO of Legend Biotech. “Legend shares ASBMT’s collaborative spirit and is committed to advancing cellular therapy worldwide.”

Globally, the leaders of Legend Biotech have extensive expertise in the area of cellular therapy and look forward to the opportunity to share these experiences with the Corporate Council. “As we investigate LCAR-B38M in multiple myeloma, our first chimeric antigen receptor T (CAR-T) cell therapy being developed in collaboration with Janssen Biotech, Inc., we look forward to contributing to the ongoing discussions with peers and thought leaders.” stated Dr. Xu.

ASBMT President, Dr. John DiPersio MD, PhD stated, “ASBMT values our corporate partners so much. The research Legend Biotech is doing in CAR-T cell therapy is very exciting, and we look forward to collaborating with them. ASBMT’s Corporate Council is an important bridge between member organizations, the work they do and the initiatives of our society.”

About CAR-T and BCMA
CAR-T cells are an innovative approach to eradicating cancer cells by harnessing the power of a patient’s own immune system. B-cell maturation antigen (BCMA) is a protein that is highly expressed on myeloma cells. By targeting BCMA, CAR-T therapies may have the potential to redefine the treatment paradigm for multiple myeloma and potentially advance towards cures for patients with the disease.

About LCAR-B38M
LCAR-B38M (also known as JNJ-68284528) is an investigational CAR-T cell therapy directed against two distinct BCMA targeting domains, which confers high avidity and affinity binding of the T cell product to the BCMA-expressing cells¹.

Globally, Legend, together with Janssen, is advancing a Phase 1b/2 trial (NCT03548207) of JNJ-68284528 to evaluate its efficacy and safety in adults with advanced R/R multiple myeloma. The study is currently enrolling patients following US Food and Drug Administration clearance of an Investigational New Drug application as announced in May 2018. In China, a Phase 2 confirmatory trial (NCT03758417) registered with the Center for Drug Evaluation (CTR20181007) is actively recruiting to further evaluate LCAR-B38M in patients with advanced relapsed or refractory (R/R) multiple myeloma.

LCAR-B38M identifies the investigational product being studied in China and JNJ-68284528 identifies the investigational product being studied in the US/EU, which are the same CAR-T construct.

About The American Society for Blood and Marrow Transplantation (ASBMT™)
The American Society for Blood and Marrow Transplantation (ASBMT™) is an international professional membership association of more than 2,200 physicians, investigators and other health care professionals from more than 45 countries. ASBMT is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. ASBMT strives to be the leading organization promoting research, education and clinical practice in the field of blood and marrow transplantation and related cellular therapy.²

About Legend Biotech
Legend Biotech is an integrated Biopharmaceutical company specialized in the discovery, and development of novel cell therapies, focused on hematologic malignancies, solid tumors, autoimmune and infectious diseases. Legend is a subsidiary of GenScript Biotech Corporation (HKEx: 1548), which operates in USA, Hong Kong, mainland China and Ireland. Learn more at www.LegendBiotech.com.

About GenScript Biotech Corporation
GenScript Biotech Corporation (HKEx: 1548) provides reagents services for researchers in basic life sciences, translational and biomedical fields, as well as pre-clinical antibody drug development, through its global operating entities located in the United States, Hong Kong, Ireland, the Netherlands, Japan and China. The diverse portfolio of GenScript encompasses extensive services in gene synthesis and molecular biology, peptide synthesis, protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology as well as variety of catalogue products for research. Two subsidiaries of GenScript, under the brand name of Bestzyme Biotech and Legend Biotech engaged in Industrial Enzymes and CAR-T as well as other forms of specific cell Immunotherapies respectively, have both made rapid progress and breakthrough in their business development. Learn more at www.GenScript.com.

Cautions Concerning Forward-Looking Statements
This information constitutes forward-looking statements relating to the business of Legend Biotech USA Inc. (“Legend”), including express or implied discussions regarding potential new products, potential new indications, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

This information was factually accurate on the date it was published. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

References

¹ Zhao W-H, et al. Abstract #955. Presented at: 60th ASH Annual Meeting, 2018.
² ASBMT Website: https://www.asbmt.org/home. Accessed January 9, 2019.

For investor-related inquiries, please contact:
Robin Meng (Vice President of Investor Relations):
robin.meng@genscript.com
For media inquiries, please contact:
media@legendbiotech.com